Cutler Group LP Reata Pharmaceuticals Inc Transaction History

Cutler Group LP

$307 Million
Q1 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 18, 2023	BUY	$79.22 - $105.37 $63,376 - $84,296	800 Added 80.0%	1,800 $183,000
Q1 2023 May 01, 2023	SELL	$30.85 - $93.17 $154,250 - $465,850	-5,000 Reduced 83.33%	1,000 $90,000
Q4 2022 Feb 07, 2023	BUY	$22.15 - $42.11 $43,103 - $81,946	1,946 Added 48.0%	6,000 $227,000
Q3 2022 Oct 25, 2022	SELL	$19.41 - $36.49 $14,208 - $26,710	-732 Reduced 15.29%	4,054 $101,000
Q2 2022 Aug 04, 2022	SELL	$20.71 - $36.5 $108,023 - $190,384	-5,216 Reduced 52.15%	4,786 $145,000
Q1 2022 Apr 14, 2022	BUY	$24.12 - $39.6 $124,700 - $204,732	5,170 Added 107.0%	10,002 $327,000
Q4 2021 Jan 18, 2022	BUY	$25.61 - $110.96 $90,454 - $391,910	3,532 Added 271.69%	4,832 $127,000
Q3 2021 Oct 26, 2021	BUY	$100.0 - $143.02 $94,600 - $135,296	946 Added 267.23%	1,300 $130,000
Q2 2021 Jul 19, 2021	SELL	$78.27 - $151.29 $39,604 - $76,552	-506 Reduced 58.84%	354 $50,000
Q1 2021 Apr 26, 2021	SELL	$94.25 - $132.81 $239,395 - $337,337	-2,540 Reduced 74.71%	860 $85,000
Q3 2020 Oct 27, 2020	BUY	$93.53 - $163.34 $303,037 - $529,221	3,240 Added 2025.0%	3,400 $331,000
Q2 2020 Jul 22, 2020	BUY	$126.3 - $176.56 $12,503 - $17,479	99 Added 162.3%	160 $24,000
Q4 2019 Feb 06, 2020	SELL	$74.57 - $217.92 $280,681 - $820,250	-3,764 Reduced 98.41%	61 $12,000
Q2 2019 Aug 09, 2019	BUY	$77.72 - $94.35 $15,544 - $18,870	200 Added 5.52%	3,825 $360,000
Q1 2019 May 10, 2019	BUY	$51.9 - $101.79 $146,617 - $287,556	2,825 Added 353.13%	3,625 $309,000
Q4 2018 Feb 05, 2019	BUY	$48.76 - $76.44 $14,628 - $22,932	300 Added 60.0%	800 $44,000
Q1 2018 May 11, 2018	BUY	$20.0 - $30.19 $2,000 - $3,019	100 Added 25.0%	500 $10,000
Q4 2017 Jan 17, 2018	BUY	$22.39 - $33.27 $8,956 - $13,308	400	400 $11,000

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Account